Jinsam Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jinsam Chang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Bouchard
Institut de Recherches Cliniques de Montréal , Montreal, Quebec
3 shared publications - Joanna Li
Medical Physics Unit, Department of Oncology, Faculty of Medicine McGill University Montréal Québec Canada
3 shared publications - Vincent Panneton
Institut de Recherches Cliniques de Montréal , Montreal, Quebec
3 shared publications - Woong-Kyung Suh
Institut de Recherches Cliniques de Montréal (IRCM)
3 shared publications - Ciriaco A. Piccirillo
Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada
1 shared publication - Fernando Alvarez
Université
1 shared publication
Latest Publications
- 12 July 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (5) , 753-762
ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations
The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.
- 12 July 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (5) , 753-762
ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations
The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.
- 15 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (2) , 301-309
ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation
ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.
- 15 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (2) , 301-309
ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation
ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.
- Open Access
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (5) , e36
Hippo Signal Transduction Mechanisms in T Cell Immunity
Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36
- 1 January 2020
- Published by XMLink in Immune Network
- Vol. 20 (5) , e36
Open AccessHippo Signal Transduction Mechanisms in T Cell Immunity
Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36